Prostate cancer / prostaatkanker
Conditions
Interventions
Prospective blood, urine, and histology sampling and imaging.
Sponsors
Erasmus MC, NKI-AvL, UMCG, UMCN
Eligibility
Inclusion criteria
Inclusion criteria: Group 1: 1. Planned to undergo prostate biopsies according to standard practice; 2. Signed informed consent. Group 2: 1. cT1-3Nx-0Mx-0 prostate cancer; 2. Scheduled for radical prostatectomy according to standard practice; 3. Signed informed consent.
Exclusion criteria
Exclusion criteria: Group 1 and group 2: 1. Known allergy to contrast agents or sulphur hexafluoride micro bubbles; 2. Documented acute prostatitis or urinary tract infections; 3. Any clinically unstable cardiac condition within 7 days prior to contrast agent administration such as: A. Evolving or ongoing myocardial infarction; B. Typical angina at rest; C. Significant worsening of cardiac symptoms; D. Recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent deterioration of ECG, laboratory or clinical findings); E. Acute cardiac failure, class III/IV cardiac failure; F. Severe cardiac rhythm disorders; G. Right-to-left shunts; H. Severe pulmonary hypertension (pulmonary artery pressure >90 mmHg) or uncontrolled systemic hypertension or respiratory distress syndrome. Group 2 only: 1. Renal insufficiency (GFR < 30 ml/min); 2. Severe cardiac condition; 3. Vulnerable for convulsions; 4. Presence of a pacemaker or other implants or clamps.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Construction of a Dutch multicenter prospective biorepository for validation of biomarker and imaging products. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Newly developed biomarkers and imaging tools that can improve the diagnosis, prognosis and therapy monitoring for prostate cancer; 2. An IT infrastructure for the integration of the complex information from biomarker analysis and (molecular) imaging, next to individual clinical data and biobank data, allowing for the future development of a Clinical Decision Support System (CDSS) that optimizes clinical decision making. | — |
Contacts
Public ContactE.A.M. Schenk-Braat
P.O. Box 2040
Outcome results
None listed